Author Topic: Seletalisib Phase II Trial published  (Read 404 times)


  • Full Member
  • ***
  • Posts: 214
Seletalisib Phase II Trial published
« on: November 18, 2019, 11:26:30 AM »
No longer relegated to being studied in murine models...

Seletalisib is a potent, selective oral inhibitor of phosphoinositide-3 kinase delta (PI3Kδ). Preclinical data have shown that the PI3Kδ pathway is upregulated within salivary glands of patients with PSS and contributes to disease pathogenesis.

It will be interesting to see what happens in lager Phase-III trials...
« Last Edit: November 18, 2019, 11:33:42 AM by markt »